|
Transcriptomic heterogeneity of metastatic disease timing within metastatic castration-sensitive prostate cancer. |
|
|
Employment - Catalent (I) |
Stock and Other Ownership Interests - Catalent (I); Merck; Pfizer |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Veracyte |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
|
|
Travel, Accommodations, Expenses - Ipsen |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Astellas Pharma; Bayer; Blue Earth Diagnostics; Decipher Biosciences; Janssen Biotech; Lantheus Medical Imaging; Myovant Sciences; tempus |
Consulting or Advisory Role - Astellas Pharma; BillionToOne |
Speakers' Bureau - Tempus |
|
|
Stock and Other Ownership Interests - Artera; Bluestar Genomics; Serimmune |
Consulting or Advisory Role - Artera; Astellas Pharma; Bayer; BlueStar Genomics; Bristol Myers Squibb; Bristol Myers Squibb (BMS); Exact Sciences; Foundation Medicine; Janssen Biotech; Myovant Sciences; Novartis; POINT Biopharma; Roivant; SerImmune; Tempus; Varian Medical Systems |
Research Funding - Zenith Epigenetics |
|
|
Consulting or Advisory Role - AAA HealthCare (Inst); Amgen (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); BMS (Inst); Daiichi Sankyo Europe GmbH (Inst); Modra Pharmaceuticals (Inst); MSD Oncology; MSD Oncology (Inst); Myriad Genetics (Inst); Novartis (Inst); Orion (Inst); PeerVoice (Inst); Pfizer (Inst); Telix Pharmaceuticals (Inst); TOLREMO (Inst); WebMD/Medscape (Inst) |
Speakers' Bureau - ASCO GU (Inst); ESMO; ESMO (Inst); German-speaking European School of Oncology (DESO); Silvia Grasso Consulting (Inst); Swiss Academy of Multidisciplinary Oncology (SAMO); Swiss Group for Clinical Cancer Research (SAKK); Swiss Group for Clinical Cancer Research (SAKK) (Inst) |
Patents, Royalties, Other Intellectual Property - Method for biomarker (WO 3752009138392 A1) |
Travel, Accommodations, Expenses - AstraZeneca |
Other Relationship - Cold Spring Harbor Laboratory (Inst); ProteoMediX |
|
|
Honoraria - Astellas Pharma; Janssen; Janssen (I) |
Consulting or Advisory Role - Abbott Laboratories; Astellas Pharma; AstraZeneca; Bayer; ESSA; Ferring; Janssen-Cilag; Medivation; Millennium; Novartis; Pfizer; Ventana Medical Systems; Veridex |
Speakers' Bureau - Astellas Pharma; AstraZeneca; Ferring; Ipsen; Janssen; Sanofi; Takeda; Ventana Medical Systems |
Research Funding - Arno Therapeutics (Inst); Innocrin Pharma (Inst); Janssen (Inst) |
Patents, Royalties, Other Intellectual Property - I am on The ICR rewards to inventors list of abiraterone acetate. |
Travel, Accommodations, Expenses - Abbott Laboratories; Astellas Pharma; Astellas Pharma (I); Bayer; ESSA; Ferring; Janssen; Janssen (I); Medivation; Pfizer; Ventana Medical Systems |
Other Relationship - Institute of Cancer Research |
|
|
Honoraria - Astellas Pharma; Bayer; Janssen; Sanofi |
Consulting or Advisory Role - Astellas Pharma; Bayer; Clovis Oncology; EUSA Pharma; Janssen; pfizer; Sanofi |
Speakers' Bureau - Astellas Pharma; AstraZeneca; Ferring; Janssen Oncology; Merck; Pierre Fabre; Sanofi |
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Janssen (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst) |
Travel, Accommodations, Expenses - Janssen; Sanofi |
|
|
Consulting or Advisory Role - Janssen Oncology |
Research Funding - AIRA Matrix (Inst); DeepBio; Exact Sciences; Ventana Medical Systems |
|
|
|
Stock and Other Ownership Interests - Veracyte |
|
|
Stock and Other Ownership Interests - Leuchemix |
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Genentech/Roche; Janssen Biotech; Lilly; Pfizer; POINT Biopharma; Sanofi |
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Dendreon; Janssen Biotech (Inst); Pfizer (Inst); Sanofi (Inst) |
Patents, Royalties, Other Intellectual Property - Leuchemix, Parthenolide, Dimethylaminoparthenolide. Exelixis: Abiraterone plus cabozantinib combination |
|
|
Honoraria - Reflexion Medical |
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer Health; Bayer Health; Dendreon; GenomeDx; Janssen; Myovant Sciences; Noxopharm; Reflexion Medical; Reflexion Medical; Regeneron |
Research Funding - Astellas Pharma (Inst); Bayer Health (Inst); Reflexion Medical (Inst) |
Patents, Royalties, Other Intellectual Property - Compounds and Methods of Use in Ablative Radiotherapy. Patent filed 3/9/2012. PCT/US2012/028475. PCT/WO/2012/122471. |
Travel, Accommodations, Expenses - Reflexion Medical |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Astellas Pharma; Bayer; Curium Pharma; Janssen-Cilag; Novartis; Telix Pharmaceuticals |
Research Funding - Bayer (Inst); Varian Medical Systems (Inst) |
Travel, Accommodations, Expenses - Ferring |